Brain Navi Biotechnology has secured TFDA certification for its KrystoLens single-use neuro-endoscope, a milestone that signals new sourcing opportunities for overseas distributors and clinic buyers seeking sterile, single-use endoscopic consumables. The certification, announced June 3, 2026, follows the product's recognition at the 22nd National Innovation Award and clears the path for commercial launch in Taiwan in the second half of 2026.
Regulatory milestone
The Taiwan Food and Drug Administration (TFDA) certification confirms KrystoLens complies with local medical device regulations, enabling Brain Navi to formally introduce the product into Taiwan's healthcare market. This regulatory step is critical for overseas buyers evaluating the device for future import or distribution in other regulated markets.
Product design and clinical value
KrystoLens is a single-use neuro-endoscope engineered to reduce cross-infection risk, improve ease of operation, and expand the surgical field of view. Its disposable design aligns with growing global demand for sterile, single-use medical consumables in minimally invasive surgery and high-quality medical imaging.
Market rollout and channel strategy
Brain Navi plans a full-scale market push in Taiwan starting in the second half of 2026, working closely with medical institutions, distribution partners, and clinical professionals. This phased launch offers early engagement opportunities for distributors and clinic buyers interested in adding single-use endoscopic consumables to their product lines.
Sourcing context
For overseas importers and clinic buyers, KrystoLens represents a potential addition to single-use medical consumables portfolios, particularly in neuro-endoscopy and minimally invasive surgery. The TFDA certification provides a regulatory benchmark that may facilitate future approvals in other jurisdictions. Buyers should monitor Brain Navi's international expansion plans and distribution partnership announcements.
Source: Read the original report | Published: June 03, 2026